Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

A pharmacological approach to inhibiting tumor growth and improving radiation response

EF 2018-19

Résumé
Prostate cancer is the most frequently diagnosed cancer in men. In solid tumors, the oxygen levels fluctuate due to abnormal tumor vasculature. The fluctuation in oxygen levels includes periods of low oxygen (hypoxia) followed by normal oxygen levels, known as reoxygenation. Hypoxia in prostate cancer causes treatment failure and poorer prognosis. Therefore, hypoxia is an attractive target to improving response to chemo- and radiotherapy. Our group has conducted a large-scale drug screen of 600 compounds to identify novel drugs that decrease proliferation of reoxygenated prostate cancer cells. The top hits of this screen were compounds called SB203580 and PI-828. The targets of these drugs are activated under hypoxic conditions, suggesting their importance in adaptation to hypoxia. My first aim is to identify whether these compounds better inhibit proliferation in reoxygenated prostate cancer cells. In my graduate training thus far, I have shown that SB203580 and PI-828 are more effective in decreasing proliferation in reoxygenated cells compared to cells in normal and low oxygen conditions. I will be conducting basic mechanistic studies of these drugs in hypoxia, normal oxygen, and reoxygenated cells to understand how these compounds exert their effects under different oxygenation conditions. My second aim is to test if SB203580 inhibits tumor growth and improves response to radiation treatment using a mouse model with tumors derived from patients. This is the first study to study SB203580 in a mouse model of cancer. This study has the potential to identify novel therapeutic agents for the treatment of hypoxic prostate cancer. Importantly, these mechanistic studies allow us to identify important pathways for adaptation to hypoxia that can be targeted for treatment.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
406512
Name
Cheung Serina
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A pharmacological approach to inhibiting tumor growth and improving radiation response
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cell Biology; Drug Discovery; Mouse Model; Prostate Cancer; Radiotherapy
Abstract
Prostate cancer is the most frequently diagnosed cancer in men. In solid tumors, the oxygen levels fluctuate due to abnormal tumor vasculature. The fluctuation in oxygen levels includes periods of low oxygen (hypoxia) followed by normal oxygen levels, known as reoxygenation. Hypoxia in prostate cancer causes treatment failure and poorer prognosis. Therefore, hypoxia is an attractive target to improving response to chemo- and radiotherapy. Our group has conducted a large-scale drug screen of 600 compounds to identify novel drugs that decrease proliferation of reoxygenated prostate cancer cells. The top hits of this screen were compounds called SB203580 and PI-828. The targets of these drugs are activated under hypoxic conditions, suggesting their importance in adaptation to hypoxia. My first aim is to identify whether these compounds better inhibit proliferation in reoxygenated prostate cancer cells. In my graduate training thus far, I have shown that SB203580 and PI-828 are more effective in decreasing proliferation in reoxygenated cells compared to cells in normal and low oxygen conditions. I will be conducting basic mechanistic studies of these drugs in hypoxia, normal oxygen, and reoxygenated cells to understand how these compounds exert their effects under different oxygenation conditions. My second aim is to test if SB203580 inhibits tumor growth and improves response to radiation treatment using a mouse model with tumors derived from patients. This is the first study to study SB203580 in a mouse model of cancer. This study has the potential to identify novel therapeutic agents for the treatment of hypoxic prostate cancer. Importantly, these mechanistic studies allow us to identify important pathways for adaptation to hypoxia that can be targeted for treatment.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cheung, Serina
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~